Physician profile
Mitchel E Phillips
NPI 1083830590
$957.73
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $147 · 2022: $119 · 2023: $149 · 2024: $61.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $211.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $244.02 | 2019-2024 | |
| Astellas Pharma US INC | $126.24 | 2019 | |
| Pfizer INC. | $101.24 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.35 | 2019-2020 | |
| Sanofi Pasteur INC. | $78.63 | 2019-2023 | |
| Antares Pharma, INC. | $62.88 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $43.07 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $42.49 | 2019 | |
| Amgen INC. | $19.72 | 2019 | |
| Exact Sciences Corporation | $18.89 | 2023 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $18.53 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.57 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.33 | 2020 | |
| Shire North American Group INC | $14.32 | 2019 | |
| Lilly USA, LLC | $14.08 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $12.35 | 2019 | |
| Merck Sharp & Dohme LLC | $11.66 | 2019 | |
| Amarin Pharma, INC. | $11.33 | 2019 | |
| Allergan, INC. | $11.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchel Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.